英夫利西单抗联合免疫抑制剂维持治疗溃疡性结肠炎的疗效

目的探讨英夫利西单抗联合免疫抑制剂维持治疗中重度溃疡性结肠炎(UC)的临床疗效。方法 36例UC患者均经使用英夫利西单抗5 mg·kg-1于第0、2和6周诱导进入缓解期后,将其按用药的不同分为3组:治疗组、对照组和联合治疗组,每组12例。治疗组采用注射用英夫利西单抗治疗,对照组采用硫唑嘌呤治疗,联合治疗组采用注射用英夫利西单抗联合硫唑嘌呤治疗。观察3组临床疗效的情况。结果治疗组、联合治疗组缓解率分别为66.7%、58.3%和总有效率分别为91.7%、91.7%,均明显高于对照组的25.0%、58.3%(均P<0.05);治疗组缓解率、总有效率与联合治疗组比较差异均无统计学意义(均P>0.05)。结论英夫利西单抗联合免疫抑制剂维持治疗中重度UC疗效显著,无明显的不良反应,可作为治疗中重度UC的选择方案之一。更多还原

Effect of Maintenance Treatment with Infliximab and Immunosuppressant on Ulcerative Colitis

Objective To investigate the curative effect of maintenance treatment with infliximab and immunosuppressant on moderate to severe ulcerative colitis （UC）. Methods Thirty-six patients with UC were given infliximab 5 mg·kg-1 for the induction of remission at week 0,2 and 6.After entering remission, patients were treated with infliximab （treatment group, n=12）, azathioprine （control group, n=12） or combination of both（combined treatment group, n=12）. Clinical efficacy was compared among the three groups. Results The remission rate and total effective rate in control group （25.0% and 58.3%, respectively） were significantly lower than those in treatment group （66.7%and 91.7%, respectively） and combined treatment group （58.3%and 91.7%,respectively）（P〈0.05）.There were no significant differences between treatment group and combined treatment group （P〉0.05）.Conclusion The maintenance treatment with infliximab and immunosuppressant is an effective option for treating moderate to severe UC and does not cause obvious adverse reactions.